BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34596686)

  • 1. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
    Noris M; Daina E; Remuzzi G
    Nephrol Dial Transplant; 2023 Feb; 38(2):283-290. PubMed ID: 34596686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3G and Ig-MPGN-treatment standard.
    Noris M; Remuzzi G
    Nephrol Dial Transplant; 2024 Jan; 39(2):202-214. PubMed ID: 37604793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
    Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].
    Rudnicki M; Windpessl M; Eller K; Odler B; Gauckler P; Neumann I; Zitt E; Regele H; Kronbichler A; Lhotta K; Säemann MD
    Wien Klin Wochenschr; 2023 Aug; 135(Suppl 5):688-695. PubMed ID: 37728653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Piras R; Breno M; Valoti E; Alberti M; Iatropoulos P; Mele C; Bresin E; Donadelli R; Cuccarolo P; Smith RJH; Benigni A; Remuzzi G; Noris M
    Front Genet; 2021; 12():670727. PubMed ID: 34211499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
    Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FHR-5 Serum Levels and
    Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
    Front Immunol; 2021; 12():720183. PubMed ID: 34566977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
    Gupta N; Wakefield DN; Clapp WL; Garin EH
    Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.
    Wada Y; Kamata M; Miyasaka R; Abe T; Kawamura S; Takeuchi K; Aoyama T; Oda T; Takeuchi Y
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [C3 glomerulopathy and MPGN - current classification].
    Hohenstein B
    Dtsch Med Wochenschr; 2020 Feb; 145(4):232-239. PubMed ID: 32069490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.
    Garam N; Prohászka Z; Szilágyi Á; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik-Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Romana Rysava ; Reiterova J; Saraga M; Tomáš Seeman ; Zieg J; Sládková E; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Csuka D
    Orphanet J Rare Dis; 2019 Nov; 14(1):247. PubMed ID: 31703608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Membranoproliferative glomerulonephritis and C3 glomerulopathy].
    Hohenstein B; Amann K; Menne J
    Internist (Berl); 2019 May; 60(5):458-467. PubMed ID: 30859280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
    Sethi S; Nester CM; Smith RJ
    Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.